Jordyn Sava is an editor for Targeted Oncology.
Worden Reviews Positive Data of Cabozantinib in RAI-Refractory DTC
October 26th 2023In an interview with Targeted Oncology, Francis P. Worden, MD, discussed data from the COSMIC-311 study which support treatment with cabozantinib for patients with radioiodine-refractory differentiated thyroid cancer.
Liver Cancer Awareness Month: Understanding and Treating HCC
October 26th 2023October is Liver Cancer Awareness Month, and strides continue to be made in the realm of liver cancer diagnosis and treatment. Two experts, Joan Culpepper-Morgan, MD, and Susanne G. Warner, MD, shed light on some of the treatment options available in the space.
Gemcitabine/Cisplatin/Nivolumab as Bladder Sparing Therapy in MIBC
October 26th 2023A phase 2 study of neoadjuvant gemcitabine, cisplatin, plus nivolumab met its co-primary end point with a positive predictive value of clinical complete response of 0.97 among patients with muscle-invasive bladder cancer.
Tepotinib Continues to Show Positive Outcomes in METex14-Skipping NSCLC
October 23rd 2023In the VISION trial, tepotinib led to clinically meaningful results in treatment-naïve and pretreated patients with METex14-skipping non–small cell lung cancer, supporting the use of MET inhibitors for this patient population.